Albireo Pharma (ALBO) 10-Q 14 May 14 2014 Q2 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information	6 Months Ended
	Mar. 31, 2014	5-May-14
Document and Entity Information [Abstract]	'	'
Entity Registrant Name	'Biodel Inc	'
Entity Central Index Key	'0001322505	'
Amendment Flag	'false	'
Current Fiscal Year End Date	'--09-30	'
Document Type	'10-Q	'
Document Period End Date	31-Mar-14	'
Document Fiscal Year Focus	'2014	'
Document Fiscal Period Focus	'Q2	'
Entity Filer Category	'Smaller Reporting Company	'
Entity Common Stock, Shares Outstanding	'	21,116,579

Consolidated_Condensed_Balance

Consolidated Condensed Balance Sheets (USD $)	Mar. 31, 2014	Sep. 30, 2013
In Thousands, unless otherwise specified
Current:	'	'
Cash and cash equivalents	$28,686	$39,781
Taxes receivable	6	6
Grant receivable	207	26
Prepaid and other assets	610	264
Total current assets	29,509	40,077
Property and equipment, net	755	1,031
Intellectual property, net	41	43
Total assets	30,305	41,151
Current:	'	'
Accounts payable	641	246
Accrued expenses:	'	'
Clinical trial expenses	25	181
Payroll and related	721	1,139
Accounting and legal fees	118	226
Severance	96	255
Other	247	319
Income taxes payable	7	75
Total current liabilities	1,855	2,441
Common stock warrant liability	3,960	6,121
Other long term liabilities	'	26
Total liabilities	5,815	8,588
Commitments	'	'
Stockholders' equity:	'	'
Convertible Preferred stock, $.01 par value; 50,000,000 shares authorized, 1,950,000 and 1,950,000 issued and outstanding	19	19
Common stock, $.01 par value; 62,500,000 shares authorized; 21,070,824 and 21,116,579 issued and outstanding	211	211
Additional paid-in capital	248,328	247,761
Deficit accumulated during the development stage	-224,068	-215,428
Total stockholders' equity	24,490	32,563
Total liabilities and stockholders' equity	$30,305	$41,151

Consolidated_Condensed_Balance1

Consolidated Condensed Balance Sheets (Parenthetical) (USD $)	Mar. 31, 2014	Sep. 30, 2013
Balance Sheets [Abstract]	'	'
Preferred stock, par value (in dollars per share)	$0.01	$0.01
Preferred stock, shares authorized	50,000,000	50,000,000
Preferred stock, shares issued	1,950,000	1,950,000
Preferred stock, shares outstanding	1,950,000	1,950,000
Common stock, par value	$0.01	$0.01
Common stock, shares authorized	62,500,000	62,500,000
Common stock, shares issued	21,116,579	21,070,824
Common stock, shares outstanding	21,116,579	21,070,824

Consolidated_Condensed_Stateme

Consolidated Condensed Statements of Operations (USD $)	3 Months Ended		6 Months Ended		124 Months Ended
In Thousands, except Share data, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013	Mar. 31, 2014	Mar. 31, 2013	Mar. 31, 2014
Income Statement [Abstract]	'	'	'	'	'
Revenue	'	'	'	'	'
Operating expenses:	'	'	'	'	'
Research and development	4,257	2,966	7,998	7,641	163,398
Government grant	-207	-29	-304	-224	-938
General and administrative	1,731	2,174	3,127	3,603	75,328
Total operating expenses	5,781	5,111	10,821	11,020	237,788
Other (income) and expense:	'	'	'	'	'
Interest and other income	-13	-12	-29	-28	-5,731
Interest expense	'	'	'	'	78
Adjustment to fair value of common stock warrant liability	426	116	-2,161	-2,112	-13,225
Loss on settlement of debt	'	'	'	'	627
Loss before tax provision (benefit)	-6,194	-5,215	-8,631	-8,880	-219,537
Tax provision (benefit)	4	5	9	9	-529
Net loss	-6,198	-5,220	-8,640	-8,889	-219,008
Charge for accretion of beneficial conversion rights	'	'	'	'	-603
Deemed dividend - warrants	'	'	'	'	-4,457
Net loss applicable to common stockholders	($6,198)	($5,220)	($8,640)	($8,889)	($224,068)
Net loss per share - basic and diluted	($0.29)	($0.37)	($0.41)	($0.63)	'
Weighted average shares outstanding - basic and diluted	21,083,237	14,182,451	21,078,404	14,179,219	'

Consolidated_Condensed_Stateme1

Consolidated Condensed Statements of Stockholders' Equity (USD $)	Total	Common Stock $.01 Par Value	Series A Preferred stock	Series B Preferred stock	Additional Paid in Capital	Accumulated Other Comprehensive Income (loss)	Accumulated Deficit during the Development Stage
In Thousands, except Share data
Balance at Dec. 03, 2003	'	'	'	'	'	'	'
Balance (in shares) at Dec. 03, 2003	'	'	'	'	'	'	'
Shares issued to employees and directors for services	'	2	'	'	-2	'	'
Shares issued to employees and directors for services (in shares)	'	831,126	'	'	'	'	'
Proceeds from sale of common stock	1,354	11	'	'	1,343	'	'
Proceeds from sale of common stock (in shares)	'	1,145,306	'	'	'	'	'
Net loss	-774	'	'	'	'	'	-774
Balance at Sep. 30, 2004	580	13	'	'	1,341	'	-774
Balance (in shares) at Sep. 30, 2004	'	1,328,432	'	'	'	'	'
Shares issued to employees and directors for services	61	'	'	'	61	'	'
Shares issued to employees and directors for services (in shares)	'	10,658	'	'	'	'	'
Additional stockholder contributions	514	'	'	'	514	'	'
Stock-based compensation	353	'	'	'	353	'	'
Private placement - Sale of preferred stock, net of issuance costs of $379 (July 2005) (Series A) and $1,795 (July 2006) (Series B) for 2005 and 2006 respectively	2,466	'	6	'	2,460	'	'
Private placement - Sale of preferred stock, net of issuance costs of $379 (July 2005) (Series A) and $1,795 (July 2006) (Series B) for 2005 and 2006 respectively (in shares)	'	'	569,000	'	'	'	'
Founder's compensation contributed to capital	63	'	'	'	63	'	'
Net loss	-3,383	'	'	'	'	'	-3,383
Balance at Sep. 30, 2005	654	13	6	'	4,792	'	-4,157
Balance (in shares) at Sep. 30, 2005	'	1,339,090	569,000	'	'	'	'
Shares issued to employees and directors for services	23	'	'	'	23	'	'
Shares issued to employees and directors for services (in shares)	'	988	'	'	'	'	'
Stock-based compensation	1,132	'	'	'	1,132	'	'
Private placement - Sale of preferred stock, net of issuance costs of $379 (July 2005) (Series A) and $1,795 (July 2006) (Series B) for 2005 and 2006 respectively	19,405	'	'	54	19,351	'	'
Private placement - Sale of preferred stock, net of issuance costs of $379 (July 2005) (Series A) and $1,795 (July 2006) (Series B) for 2005 and 2006 respectively (in shares)	'	'	'	5,380,711	'	'	'
July 2006 - Series B preferred stock units issued July 2006 to settle debt	3,202	'	'	8	3,194	'	'
July 2006 - Series B preferred stock units issued July 2006 to settle debt (in shares)	'	'	'	817,468	'	'	'
Accretion of fair value of beneficial conversion charge	'	'	'	'	603	'	-603
Net loss	-8,068	'	'	'	'	'	-8,068
Balance at Sep. 30, 2006	16,348	13	6	62	29,095	'	-12,828
Balance (in shares) at Sep. 30, 2006	'	1,340,078	569,000	6,198,179	'	'	'
Stock-based compensation	4,224	'	'	'	4,224	'	'
Proceeds from sale of common stock	78,755	14	'	'	78,741	'	'
Proceeds from sale of common stock (in shares)	'	1,437,500	'	'	'	'	'
Conversion of preferred stock	'	16	-6	-62	52	'	'
Conversion of preferred stock (in shares)	'	1,601,749	-569,000	-6,198,179	'	'	'
Shares issued to employees, non-employees and directors for services	16	'	'	'	16	'	'
Shares issued to employees, non-employees and directors for services (in shares)	'	732	'	'	'	'	'
Stock options exercised	5	'	'	'	5	'	'
Stock options exercised (in shares)	'	885	'	'	'	'	'
Warrants exercised	423	7	'	'	416	'	'
Warrants exercised (in shares)	'	659,226	'	'	'	'	'
Deemed dividend - warrants	'	'	'	'	4,457	'	-4,457
Net loss	-22,548	'	'	'	'	'	-22,548
Balance at Sep. 30, 2007	77,223	50	'	'	117,006	'	-39,833
Balance (in shares) at Sep. 30, 2007	'	5,040,170	'	'	'	'	'
Stock-based compensation	6,503	'	'	'	6,503	'	'
Proceeds from sale of common stock	46,817	8	'	'	46,809	'	'
Proceeds from sale of common stock (in shares)	'	815,000	'	'	'	'	'
Proceeds from the sale of stock - ESPP	181	'	'	'	181	'	'
Proceeds from the sale of stock - ESPP (in shares)	'	3,596	'	'	'	'	'
Stock options exercised	902	1	'	'	901	'	'
Stock options exercised (in shares)	'	43,600	'	'	'	'	'
Warrants exercised	112	'	'	'	112	'	'
Warrants exercised (in shares)	'	19,802	'	'	'	'	'
RSUs converted to common stock	172	'	'	'	172	'	'
RSUs converted to common stock (in shares)	'	2,428	'	'	'	'	'
Net unrealized gain (loss) on Marketable Securities	-62	'	'	'	'	-62	'
Net loss	-43,361	'	'	'	'	'	-43,361
Balance at Sep. 30, 2008	88,487	59	'	'	171,684	-62	-83,194
Balance (in shares) at Sep. 30, 2008	'	5,924,596	'	'	'	'	'
Stock-based compensation	5,064	'	'	'	5,064	'	'
Proceeds from the sale of stock - ESPP	170	'	'	'	170	'	'
Proceeds from the sale of stock - ESPP (in shares)	'	21,863	'	'	'	'	'
Stock options exercised	25	'	'	'	25	'	'
Stock options exercised (in shares)	'	4,413	'	'	'	'	'
Net unrealized gain (loss) on Marketable Securities	62	'	'	'	'	62	'
Net loss	-43,270	'	'	'	'	'	-43,270
Balance at Sep. 30, 2009	50,538	59	'	'	176,943	'	-126,464
Balance (in shares) at Sep. 30, 2009	'	5,950,872	'	'	'	'	'
Stock-based compensation	5,621	'	'	'	5,621	'	'
Registered direct offering or financing	8,712	6	'	'	8,706	'	'
Registered direct offering or financing (in shares)	'	599,550	'	'	'	'	'
Initial value of warrants issued in registered direct offering	-2,915	'	'	'	-2,915	'	'
Proceeds from the sale of stock - ESPP	325	1	'	'	324	'	'
Proceeds from the sale of stock - ESPP (in shares)	'	41,393	'	'	'	'	'
Stock options exercised	68	'	'	'	68	'	'
Stock options exercised (in shares)	'	8,076	'	'	'	'	'
Net unrealized gain (loss) on Marketable Securities	1	'	'	'	'	1	'
Net loss	-38,290	'	'	'	'	'	-38,290
Balance at Sep. 30, 2010	24,060	66	'	'	188,747	1	-164,754
Balance (in shares) at Sep. 30, 2010	'	6,599,891	'	'	'	'	'
Stock-based compensation	4,920	'	'	'	4,920	'	'
Registered direct offering or financing	27,961	30	18	'	27,913	'	'
Registered direct offering or financing (in shares)	'	3,018,736	1,813,944	'	'	'	'
Initial value of warrants issued in registered direct offering	-9,438	'	'	'	-9,438	'	'
Proceeds from the sale of stock - ESPP	118	'	'	'	118	'	'
Proceeds from the sale of stock - ESPP (in shares)	'	17,051	'	'	'	'	'
Stock options exercised (in shares)	'	104	'	'	'	'	'
Warrants exercised	50	'	'	'	50	'	'
Warrants exercised (in shares)	'	10,549	'	'	'	'	'
RSUs converted to common stock (in shares)	'	15,537	'	'	'	'	'
Net unrealized gain (loss) on Marketable Securities	-1	'	'	'	'	-1	'
Net loss	-10,592	'	'	'	'	'	-10,592
Balance at Sep. 30, 2011	37,078	96	18	'	212,310	'	-175,346
Balance (in shares) at Sep. 30, 2011	'	9,661,868	1,813,944	'	'	'	'
Proceeds from the sale of unregistered securities	17,078	43	'	36	16,999	'	'
Proceeds from the sale of unregistered securities, shares	'	4,250,020	'	3,605,607	'	'	'
Initial value of warrants issued in private placement financing	-4,832	'	'	'	-4,832	'	'
Stock-based compensation	1,828	'	'	'	1,828	'	'
Proceeds from the sale of stock - ESPP	27	'	'	'	27	'	'
Proceeds from the sale of stock - ESPP (in shares)	'	10,776	'	'	'	'	'
RSUs issued to settle bonus liability	584	2	'	'	582	'	'
RSUs issued to settle bonus liability, (in shares)	'	191,719	'	'	'	'	'
RSUs converted to common stock	'	1	'	'	-1	'	'
RSUs converted to common stock (in shares)	'	60,409	'	'	'	'	'
Net loss	-20,747	'	'	'	'	'	-20,747
Company re-purchase of fractional shares from the reverse stock split	'	-247	'	'	'	'	'
Balance at Sep. 30, 2012	31,016	142	18	36	226,913	'	-196,093
Balance (in shares) at Sep. 30, 2012	'	14,174,545	1,813,944	3,605,607	'	'	'
Stock-based compensation	1,538	'	'	'	1,538	'	'
Proceeds from sale of common stock	19,239	47	'	'	19,192	'	'
Proceeds from sale of common stock (in shares)	'	4,718,767	'	'	'	'	'
Conversion of preferred stock	'	22	-18	-17	13	'	'
Conversion of preferred stock (in shares)	'	2,109,090	-1,813,944	-1,655,607	'	'	'
Proceeds from the sale of stock - ESPP	30	'	'	'	30	'	'
Proceeds from the sale of stock - ESPP (in shares)	'	13,395	'	'	'	'	'
Stock options exercised	75	'	'	'	75	'	'
Stock options exercised (in shares)	'	30,250	'	'	'	'	'
RSUs converted to common stock (in shares)	'	24,777	'	'	'	'	'
Net loss	-19,335	'	'	'	'	'	-19,335
Balance at Sep. 30, 2013	32,563	211	'	19	247,761	'	-215,428
Balance (in shares) at Sep. 30, 2013	'	21,070,824	'	1,950,000	'	'	'
Stock-based compensation	509	'	'	'	509	'	'
Proceeds from the sale of stock - ESPP	10	'	'	'	10	'	'
Proceeds from the sale of stock - ESPP (in shares)	'	5,046	'	'	'	'	'
Stock options exercised	48	'	'	'	48	'	'
Stock options exercised (in shares)	'	19,241	'	'	'	'	'
RSUs converted to common stock	'	'	'	'	'	'	'
RSUs converted to common stock (in shares)	'	21,468	'	'	'	'	'
Net loss	-8,640	'	'	'	'	'	-8,640
Balance at Mar. 31, 2014	$24,490	$211	'	$19	$248,328	'	($224,068)
Balance (in shares) at Mar. 31, 2014	'	21,116,579	'	1,950,000	'	'	'

Consolidated_Condensed_Stateme2

Consolidated Condensed Statements of Stockholders' Equity (Parenthetical) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2005	Sep. 30, 2006
	Series A Preferred stock	Series B Preferred stock
Issuance costs of Preferred Stock, Private Placement (in dollars)	$379	$1,795

Consolidated_Condensed_Stateme3

Consolidated Condensed Statements of Cash Flows (USD $)	6 Months Ended		124 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013	Mar. 31, 2014
Cash flows from operating activities:	'	'	'
Net loss	($8,640)	($8,889)	($219,008)
Adjustments to reconcile net loss to net cash used in operating activities:	'	'	'
Depreciation and amortization	310	326	5,754
Founder's compensation contributed to capital	'	'	271
Stock-based compensation for employees and directors	509	890	29,671
Stock-based compensation for non-employees	'	'	2,274
Loss on settlement of debt	'	'	627
Write-off of capitalized patent expense	'	'	246
Write-off of loan to related party	'	'	41
Adjustment to fair value of common stock warrant liability	-2,161	-2,112	-13,225
(Increase) decrease in:	'	'	'
Income taxes receivable	'	'	-6
Grant receivable	-181	60	-206
Other receivables	'	8	-1
Prepaid expenses and other assets	-346	-658	-610
Increase (decrease) in:	'	'	'
Accounts payable	395	27	641
Income taxes payable	-68	-4	7
Accrued expenses and long term liabilities	-939	-716	2,011
Total adjustments	-2,481	-2,179	27,495
Net cash used in operating activities	-11,121	-11,068	-191,513
Cash flows from investing activities:	'	'	'
Purchase of property and equipment	-32	-87	-6,499
Purchase of marketable securities	'	'	-31,614
Sale of marketable securities	'	'	31,614
Capitalized intellectual properties	'	'	-298
Loan to related party	'	'	-41
Net cash used in investing activities	-32	-87	-6,838
Cash flows from financing activities:	'	'	'
Options exercised	48	'	1,123
Warrants exercised	'	'	585
Net proceeds from employee stock purchase plan	10	6	861
Deferred public offering costs	'	'	-1,458
Stockholder contribution	'	'	1,660
Net proceeds from sale of unregistered common stock - private placement	'	'	8,587
Net proceeds from sale of common stock	'	'	180,257
Proceeds from bridge financing	'	'	2,575
Net cash provided by financing activities	58	6	227,037
Net (decrease) increase in cash and cash equivalents	-11,095	-11,149	28,686
Cash and cash equivalents, beginning of period	39,781	39,050	'
Cash and cash equivalents, end of period	28,686	27,901	28,686
Cash paid for interest and income taxes was:	'	'	'
Interest	'	'	9
Income taxes	14	12	352
Non-cash financing and investing activities:	'	'	'
Warrants issued in connection with registered direct offering	'	'	12,353
Warrants issued in connection with unregistered common stock private placement	'	'	4,832
Settlement of debt with Series B preferred stock	'	'	3,202
Accrued expenses settled with Series B preferred stock	'	'	150
Deemed dividend - warrants	'	'	4,457
Accretion of fair value of beneficial charge on preferred stock	'	'	603
Conversion of convertible preferred stock to common stock	'	'	68
Issuance of restricted stock units to settle accrued bonus	'	'	584
Series A preferred stock 2005	'	'	'
Cash flows from financing activities:	'	'	'
Net proceeds from sale of preferred stock	'	'	2,466
Series A preferred stock 2011	'	'	'
Cash flows from financing activities:	'	'	'
Net proceeds from sale of preferred stock	'	'	2,685
Series B preferred stock 2006	'	'	'
Cash flows from financing activities:	'	'	'
Net proceeds from sale of preferred stock	'	'	19,205
Series B preferred stock 2012	'	'	'
Cash flows from financing activities:	'	'	'
Net proceeds from sale of preferred stock	'	'	$8,491

Business_and_Basis_of_Presenta

Business and Basis of Presentation	6 Months Ended
	Mar. 31, 2014
Business and Basis of Presentation [Abstract]	'
Business and Basis of Presentation	'
	1. Business and Basis of Presentation
	Business
	Biodel Inc. and its wholly owned subsidiary (collectively, "Biodel" or the "Company", and formerly Global Positioning Group Ltd.) is a development stage specialty pharmaceutical company located in Danbury, Connecticut. The Company was incorporated in the State of Delaware on December 3, 2003 and commenced operations in January 2004. The Company formed a wholly owned subsidiary in the United Kingdom in October 2011 ("Biodel UK Limited"). This subsidiary has been inactive since its inception. The Company focuses on the development and commercialization of innovative treatments for diabetes that may be safer, more effective and more convenient for patients.
	The Company is developing room temperature stable glucagon presentations for use as a rescue treatment for diabetes patients experiencing severe hypoglycemia, or very low concentrations of blood glucose. The leading presentation uses a proprietary device from Unilife Corporation. The device, which is being customized for use in emergency situations, is a dual-chamber design that automatically reconstitutes lyophilized glucagon with a liquid diluent immediately prior to injection, and it features automatic needle retraction on full dose delivery. The Company expects to submit an Investigational New Drug application to the U.S. Food and Drug Administration (the "FDA") for its dual-chamber glucagon rescue product in the second half of calendar year 2014 and initiate a pivotal clinical trial in the fourth calendar quarter of 2014. The Company has entered into a customization and commercial supply agreement with Unilife Medical Solutions, Inc., a wholly owned subsidiary of Unilife Corporation, to acquire an exclusive, sublicensable, worldwide license to the dual-chamber device for use with glucagon. The Company has also entered into a long-term commercial supply agreement with Becton, Dickinson and Company for worldwide exclusive rights to its Uniject disposable injection system for use with liquid glucagon formulations. The Company is currently assessing several formulations of liquid glucagon in pre-clinical studies.
	The Company is also developing proprietary insulin formulations that are designed to be more rapid-acting than the formulations currently available to Type 1 and Type 2 diabetes patients. The Company refers to these as "ultra rapid acting" formulations. The Company's most advanced ultra-rapid-acting insulin formulation, BIOD-123, combines recombinant human insulin, or RHI, with the Company's proprietary combination of excipients to increase the rate of absorption following subcutaneous injection when compared to other commercially available insulin formulations, including "rapid-acting" mealtime insulin analogs such as Humalog®, marketed by Eli Lilly, NovoLog®, marketed by Novo Nordisk, and Apidra®, marketed by Sanofi. The Company is also using its proprietary excipients to develop ultra-rapid-acting insulin analog-based formulations using either insulin lispro, the active pharmaceutical ingredient in Humalog®, or insulin aspart, the active pharmaceutical ingredient in NovoLog®.
	In addition to BIOD-123, the Company has other RHI-based formulations in earlier stages of development. In particular, the Company is developing ultra-rapid-acting formulations of concentrated insulin that are characterized in pre-clinical studies with diabetic swine by a rapid onset of action and a prolonged duration of action. The Company believes these formulations could address an unmet medical need for an insulin with an initial rate of absorption superior to that of existing concentrated insulins and prandial/basal pre-mixed insulins. In January 2014, the Company announced preliminary results from a Phase 1 clinical trial with BIOD-531, the Company's candidate for an ultra-rapid-acting concentrated insulin formulation. The results of the clinical trial confirmed earlier findings in diabetic swine that BIOD-531 is characterized by rapid absorption and onset of action, and an extended duration of action that may be suitable for basal insulin needs.
	Basis of Presentation
	The consolidated financial statements have been prepared by the Company and are unaudited. These consolidated financial statements include Biodel UK Limited. This subsidiary has been inactive since its inception. All intercompany balances and transactions have been eliminated. In the opinion of management, the Company has made all adjustments (consisting of normal recurring accruals) necessary to fairly present the financial position and results of operations for the interim periods presented. Certain information and footnote disclosures normally included in the annual financial statements prepared in accordance with generally accepted accounting principles in the United States of America ("US GAAP") have been consolidated or omitted. These consolidated financial statements should be read in conjunction with the September 30, 2013 audited financial statements and accompanying notes included in the Company's Annual Report on Form 10-K for the fiscal year ended September 30, 2013, filed with the Securities and Exchange Commission on December 20, 2013. The results of operations for the three and six months ended March 31, 2014 are not necessarily indicative of the operating results for the full fiscal year or any other interim period.
	The Company is in the development stage, as defined by Financial Accounting Standards Board ("FASB") ASC 915 (prior authoritative literature: Statement of Financial Accounting Standards No. 7), "Accounting and Reporting by Development Stage Enterprises", as its primary activities since incorporation have been establishing its facilities, recruiting personnel, conducting research and development, business development, business and financial planning and raising capital.
	On June 11, 2012, the Company effected a one-for-four reverse split of its outstanding common stock. All references in these financial statements and accompanying notes to units of common stock or per share amounts are reflective of the reverse split for all periods reported. (See Note 5.)

Fair_Value_of_Financial_Instru

Fair Value of Financial Instruments	6 Months Ended
	Mar. 31, 2014
Fair Value of Financial Instruments [Abstract]	'
Fair Value Measurements	'
	2. Fair Value of Financial Instruments
	The carrying amounts of the Company's financial instruments, which include cash and cash equivalents, and accounts payable, approximate their fair values due to their short term maturities.
	ASC Topic 820 ("ASC 820", originally issued as SFAS No. 157, Fair Value Measurements) applies under other accounting pronouncements that require or permit fair value measurements, the FASB having previously concluded in those accounting pronouncements that fair value is the relevant measurement attribute. Accordingly, ASC 820 does not require any new fair value measurements. The fair value framework requires the categorization of assets and liabilities into three levels based upon the assumptions (inputs) used to price the assets or liabilities. The three levels of inputs used are as follows:
	Level 1 — Quoted prices in active markets for identical assets or liabilities.
	Level 2 — Observable inputs other than quoted prices included in Level 1, such as quoted prices for similar assets and liabilities in active markets; quoted prices for identical or similar assets and liabilities in markets that are not active; or other inputs that are observable or can be corroborated by observable market data.
	Level 3 — Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. This includes certain pricing models, discounted cash flow methodologies and similar techniques that use significant unobservable inputs.
	As of September 30, 2013 and March 31, 2014, the Company had assets and liabilities that fell under the scope of ASC 820. The Company used the Black-Scholes valuation model to determine the fair value of the Company's warrant liability as of September 30, 2013 and March 31, 2014 for the warrants issued in the May 2011 and June 2012 financings (as defined in Note 9). The Black-Scholes valuation model takes into account, as of the valuation date, factors including the current exercise price, the life of the warrant, the current price of the underlying stock and its expected volatility, expected dividends on the stock, and the risk-free interest rate for the term of the warrant. Accordingly, the Company's fair value measurements of its cash and cash equivalents and restricted cash are classified as a Level 1 input and the warrant liability as a Level 3 input.
	The fair value of the Company's financial assets and liabilities carried at fair value and measured on a recurring basis are as follows:
		Description		Fair Value at			Quoted Prices in		Significant Other		Significant
				31-Mar-14			Active Markets for		Observable		Unobservable
							Identical Assets		Market Inputs		Inputs
							(Level 1)		(Level 2)		(Level 3)
		Assets:
		Cash and cash equivalents	$	28,686		$	28,686	$	—	$	—
		Subtotal		28,686			28,686		—		—
		Liabilities:
		Common stock warrant liability (see Note 9)		(3,960	)		—		—		(3,960	)
		Subtotal		(3,960	)		—		—		(3,960	)
		Total	$	24,726		$	28,686	$	—	$	(3,960	)
		Description		Fair Value at			Quoted Prices in		Significant Other		Significant
				30-Sep-13			Active Markets for		Observable		Unobservable
							Identical Assets		Market Inputs		Inputs
							(Level 1)		(Level 2)		(Level 3)
		Assets:
		Cash and cash equivalents	$	39,781		$	39,781	$	—	$	—
		Subtotal		39,781			39,781		—		—
		Liabilities:
		Common stock warrant liability (see Note 9)		(6,121	)		—		—		(6,121	)
		Subtotal		(6,121	)		—		—		(6,121	)
		Total	$	33,660		$	39,781	$	—	$	(6,121	)
	The Company recognizes transfers into and out of the levels indicated above on the actual date of the event or change in circumstances that caused the transfer of change. All changes within Level 3 can be found in the following Level 3 reconciliation table below:
		Balance at September 30, 2013	$	(6,121	)
		Decrease in fair value of common stock warrant liability		2,161
		Balance at March 31, 2014	$	(3,960	)
	The unrealized gains or losses on the derivative liabilities are recorded as a change in fair value of derivative liabilities in the Company's statement of operations. A financial instrument's level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. At each reporting period, the Company reviews the assets and liabilities that are subject to ASC Topic 815-40. At each reporting period, all assets and liabilities for which the fair value measurement is based on significant unobservable inputs or instruments which trade infrequently and therefore have little or no price transparency are classified as Level 3.

PreLaunch_Inventory

Pre-Launch Inventory	6 Months Ended
	Mar. 31, 2014
Pre-Launch Inventory [Abstract]	'
Pre-Launch Inventory	'
	3. Pre-Launch Inventory
	Inventory costs associated with product candidates that have not yet received regulatory approval are capitalized if the Company believes there is probable future commercial use and future economic benefit. If the probability of future commercial use and future economic benefit cannot be reasonably determined, then pre-launch inventory costs associated with such product candidates are expensed as research and development expense during the period the costs are incurred. Because all of its product candidates are in early stages of preclinical or clinical development, the Company currently expenses all purchases of pre-launch inventory as research and development, and expects to continue to do so until it can determine the probability of regulatory approval for the applicable product candidate.

StockBased_Compensation

Stock-Based Compensation	6 Months Ended
	Mar. 31, 2014
Stock-Based Compensation [Abstract]	'
Stock-Based Compensation	'
	4. Stock-Based Compensation
	In March 2013, the Company's stockholders approved an amendment to and restatement of the Company's 2010 Stock Incentive Plan (as amended and restated the "2010 Plan"). The 2010 Plan replaced the Company's 2004 Stock Incentive Plan and 2005 Non-Employee Directors Stock Option Plan. Stock options are granted at an exercise price equal to the Company's closing stock price on the date of the grant. Stock options vest over a period of up to four years with a contractual life of seven years. The Company estimates the fair value using the Black-Scholes pricing model. The Company uses the following assumptions in its Black Scholes valuation calculations:
	Risk-free rate - The Company uses interest rates based on the yield of US Treasury strips on the date the award is granted and the expected term of the award.
	Forfeitures - The Company estimates forfeitures based on actual historical and estimated future forfeitures.
	Dividends - The Company has assumed that dividends will not be paid.
	Volatility - The Company uses its historical volatility.
	Expected term - The expected option term represents the period that stock based awards are expected to be outstanding based on the simplified method provided in Staff Accounting Bulletin ("SAB") No. 107, Share-Based Payment, ("SAB No. 107"), which averages an award's weighted-average vesting period and expected term for "plain vanilla" share options. Under SAB No. 107, options are considered to be "plain vanilla" if they have the following basic characteristics: (i) granted "at-the money"; (ii) exercisability is conditioned upon service through the vesting date; (iii) termination of service prior to vesting results in forfeiture; (iv) limited exercise period following termination of service; and (v) options are non-transferable and non-hedgeable.
	In December 2007, the SEC issued SAB No. 110, Share-Based Payment, ("SAB No. 110"). SAB No. 110 was effective January 1, 2008 and expresses the views of the Staff of the SEC with respect to extending the use of the simplified method, as discussed in SAB No. 107, in developing an estimate of the expected term of "plain vanilla" share options in accordance with ASC Topic 718. The Company will continue to use the simplified method until it has the historical data necessary to provide a reasonable estimate of expected life in accordance with SAB No. 107, as amended by SAB No. 110. For the expected term, the Company has "plain-vanilla" stock options, and therefore used a simple average of the vesting period and the contractual term for options granted subsequent to January 1, 2006 as permitted by SAB No. 107.The Company expenses ratably over the vesting period the cost of the stock options granted to employees and non-employee directors. The total stock based compensation cost for the three and six months ended March 31, 2014 which included stock based compensation charges related to the Company's 2005 Employee Stock Purchase Plan was $214 and $509, respectively. In comparison, the total compensation cost for the three and six months ended March 2013 was $346 and $890, respectively.
	At March 31, 2014, the total compensation cost related to non-vested options not yet recognized was $1,444, which will be recognized over the next four years assuming the employees complete their service period for vesting of the options.
				Number			Weighted			Weighted			Aggregate
							Average			Average			Intrinsic
							Exercise			Remaining			Value
							Price			Contractual
										Life in Years
		Outstanding options, September 30, 2013		1,920,051		$	22.26			4		$	445
		Granted		1,267,000			2.41						—
		Exercised		(19,241	)		2.48
		Forfeited, expired		(282,285	)		5.96						—
		Outstanding options, March 31, 2014		2,885,525		$	15.27			5			531
		Exercisable options, March 31, 2014		1,441,668		$	28.09			3		$	50
	The Black-Scholes pricing model assumptions for the three and six months ended March 31, 2013 and 2014 are determined as discussed below:
				Three Months Ended						Six Months Ended
				March 31,						March 31,
				2013			2014			2013			2014
		Expected life (in years)		2.39 - 3.77			3.77 - 4.75			2.39 - 4.75			3.77 - 4.75
		Expected volatility		80 - 87	%		73 - 83	%		80 - 90	%		70 - 83	%
		Expected dividend yield		0	%		0	%		0	%		0	%
		Risk-free interest rate		0.25 - 0.36	%		0.69 - 0.78	%		0.25 - 0.75	%		0.58 - 0.78	%
		Weighted average grant date fair value	$	2.86		$	3.35		$	2.43		$	2.41
	Restricted Stock Units
	The Company grants restricted stock units ("RSUs") to executive officers and employees pursuant to the 2010 Plan from time to time. There is no direct cost to the recipients of RSUs, except for any applicable taxes.
	Each RSU award that was granted to the Company's executive officers and employees represents one share of common stock. Each year following the annual vesting date, between January 1st and March 15th, the Company will issue common stock for each vested RSU. During the period when the RSU is vested but not distributed, the RSUs cannot be transferred and the grantee has no voting rights. If the Company declares a dividend, RSU recipients will receive payment based upon the percentage of RSUs that have vested prior to the date of declaration. The costs of the awards, determined as the fair market value of the shares on the grant date, are expensed per the vesting schedule outlined in the award.
	Based on historical experience of option cancellations, the Company has estimated an annualized forfeiture rate of 7.5%. Forfeiture rates will be adjusted over the requisite service period when actual forfeitures differ, or are expected to differ, from the estimate.
	The stock-based compensation expense associated with the RSUs has been recorded in the statement of operations and in additional paid-in-capital on the balance sheets is as follows:
				Three Months Ended						Six Months Ended
				March 31,						March 31,
				2013			2014			2013			2014
		Stock compensation expense — RSUs	$	110		$	0		$	199		$	54
	At March 31, 2014, all of the stock-based compensation expense related to RSU awards granted under the 2004 Stock Incentive Plan and the 2010 Plan has been recognized. The following table summarizes RSU activity from October 1, 2013 through March 31, 2014:
				Shares			Weighted
							Average
							Grant-Date
							Fair Value
		Non-vested and outstanding balance at October 1, 2013		31,296		$	10.48
		Changes during the period:
		RSUs granted		—			—
		RSUs converted to common stock		(21,468	)		10.48
		RSUs withheld for tax payments		(9,828	)		10.48
		Non-vested and outstanding RSU balance at March 31, 2014		—		$	—
	2005 Employee Stock Purchase Plan
	The Company's 2005 Employee Stock Purchase Plan (the "Purchase Plan") was adopted by its board of directors and approved by its stockholders on March 20, 2007. The Purchase Plan became effective upon the closing of the Company's initial public offering. The Purchase Plan is intended to qualify as an employee stock purchase plan within the meaning of Section 423 of the Internal Revenue Code.
	Under the Purchase Plan, eligible employees may contribute up to 15% of their eligible earnings for the period of that offering withheld for the purchase of common stock under the Purchase Plan. The employee's purchase price is equal to the lower of: 85% of the fair market value per share on the start date of the offering period in which the employee is enrolled or 85% of the fair market value per share on the semi-annual purchase date. The Purchase Plan imposes a limitation upon a participant's right to acquire common stock if immediately after the purchase the employee would own 5% or more of the total combined voting power or value of the Company's common stock or of any of its affiliates. The Purchase Plan provides for an automatic rollover when the purchase price for a new offering period is lower than previously established purchase price(s). The Purchase Plan also provides for a one-time election that allows an employee the opportunity to enroll into a new offering period when the new offering is higher than their current offering price. This election must be made within 30 days from the start of a new offering period. Offering periods are twenty-seven months in length. The compensation charge/(credit) in connection with the Purchase Plan for the three and six months ended March 31, 2014 was $2 and $1, respectively. In comparison, for the three and six months ended March 31, 2013, the Company expensed $3 and $(7), respectively.
	An aggregate of 500,000 shares of common stock are reserved for issuance pursuant to purchase rights to be granted to the Company's eligible employees under the Purchase Plan. The Purchase Plan shares are replenished annually on the first day of each calendar year by virtue of an evergreen provision. The provision allows for share replenishment equal to the lesser of 1% of the total number of shares of common stock outstanding on that date or 25,000 shares. As of March 31, 2013 and 2014, a total of 377,646 and 386,880 shares, respectively, were reserved and available for issuance under the Purchase Plan. As of March 31, 2013 and 2014, the Company has issued 97,354 and 113,120 shares, respectively, under the Purchase Plan.

Reverse_Stock_Splits

Reverse Stock Splits	6 Months Ended
	Mar. 31, 2014
Reverse Stock Splits [Abstract]	'
Reverse Stock Splits	'
	5. Reverse Stock Split
	On June 11, 2012, the Company amended its certificate of incorporation in order to effect a one-for-four reverse split of its outstanding common stock and to fix on a post-split basis the number of authorized shares of its common stock at 25,000,000 (reduced from 100,000,000 authorized shares). As a result of the reverse stock split, each share of Company common stock outstanding at the effective time was automatically changed into one-quarter of a share of common stock. No fractional shares were issued in connection with the reverse stock split, and cash of $0.3 was paid in lieu of fractional shares. Also as a result of the reverse stock split, the number of shares of common stock subject to outstanding options, restricted stock units and warrants issued by the Company and the number of shares reserved for future issuance under the Company’s stock plans have been reduced by a factor of four. There was no alteration to the par value of the common stock or any modification of the voting rights or other terms thereof. All references in these financial statements and accompanying notes to units of common stock or per share amounts are reflective of the reverse stock split for all periods reported.

Stockholders_Equity

Stockholders' Equity	6 Months Ended
	Mar. 31, 2014
Stockholders' Equity [Abstract]	'
Stockholders' Equity	'
	6. Stockholders' Equity
	On November 1, 2012, the Company's shareholders approved an amendment to the Company's certificate of incorporation to increase the number of authorized shares of common stock, and on December 20, 2012, the Company amended its certificate of incorporation in order to effect an increase in the number of shares of its authorized common stock, par value $.01, from 25,000,000 to 62,500,000 shares.
	For the year ended September 30, 2013, 1,655,607 shares of the Company's Series B Convertible Preferred stock were converted into 1,655,607 share of common stock.
	In August 2013, 1,813,944 shares of the Company's Series A Convertible Preferred Stock, convertible at a 4:1 ratio, were converted into 453,483 shares of common stock.

Income_Taxes

Income Taxes	6 Months Ended
	Mar. 31, 2014
Income Taxes [Abstract]	'
Income Taxes	'
	7. Income Taxes
	The Company accounts for income taxes under FASB ASC 740-10-25 ("ASC 740-10-25"), Accounting for Income Taxes. Under ASC 740-10-25, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. Under ASC 740-10-25, the effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. The Company files U.S. federal and state tax returns and has determined that its major tax jurisdictions are the United States and Connecticut. The tax years ended in 2004 through 2013 remain open and subject to examination by the appropriate governmental agencies in the United States and Connecticut.
	Section 382 of the Internal Revenue Code imposes limitations on the use of U.S. federal net operating losses ("NOLs") upon a greater than 50% change in ownership in the Company within the three-year period preceding the date of ownership change. The Company's NOLs will continue to be available to offset taxable income (until such NOLs are either used or expire) subject to the Section 382 annual limitation. If the Section 382 annual limitation amount is not fully utilized in a particular tax year, then the unused portion from that particular tax year will be added to the Section 382 annual limitation in subsequent years. The Company has determined that ownership change, under Section 382, occurred as a result of the May 2011financing and therefore, the ability to utilize its current NOLs is further limited.
	The Company has approximately $58 million of NOLs at the end of the prior fiscal year, which, if not used, expire beginning in 2024 through 2033.
	The Company's effective tax rate for the three and six months ended March 31, 2013 and 2014 was 0% and differs from the federal statutory rate of 34% primarily due to the effects of state income taxes and a full valuation allowance offsetting its deferred tax assets.

Net_Loss_per_Share

Net Loss per Share	6 Months Ended
	Mar. 31, 2014
Net Loss Per Share [Abstract]	'
Net Loss per Share	'
	8. Net Loss per Share
	Basic and diluted net loss per share has been calculated by dividing net loss applicable to common stockholders by the weighted average number of common shares outstanding during the period. All potentially dilutive common shares have been excluded from the calculation of weighted average common shares outstanding, as their inclusion would be anti-dilutive.
	The amount of options, common shares underlying warrants, common shares issuable upon conversion of preferred stock and RSUs excluded are as follows:
			Three Months Ended		Six Months Ended
			March 31,		March 31,
			2013	2014	2013	2014
		Common shares underlying warrants issued for common stock	5,006,398	5,006,398	5,006,398	5,006,398
		Common shares issuable upon conversion of Series A Preferred Stock	453,486	—	453,486	—
		Common shares issuable upon conversion of Series B Preferred Stock	3,605,607	1,950,000	3,605,607	1,950,000
		Stock options	1,983,297	2,885,525	1,983,297	2,885,525
		Restricted stock units outstanding	31,302	—	31,302	—

Financings

Financings	6 Months Ended
	Mar. 31, 2014
Financing [Abstract]	'
Financings	'
	9. Financings
	June 2013 Public Offering
	On June 24, 2013, the Company completed an underwritten public offering of 4,482,760 shares of its common stock at a price to the public of $4.35 per share. On July 22, 2013, after the completion of its third fiscal quarter, the Company issued 236,007 additional shares of common stock, at the public offering price of $4.35 per share, in connection with the underwriters' exercise of a portion of their over-allotment option. The Company received net proceeds from this offering, after deducting underwriting discounts, commissions and expenses, of $19.3 million.
	June 2012 Private Placement
	In June 2012, the Company completed a private placement (the "2012 Private Placement") of an aggregate of 4,250,020 shares of the Company's common stock, 3,605,607 shares of the Company's Series B Convertible Preferred Stock and warrants to purchase an aggregate of 2,749,469 shares of common stock at an exercise price of $2.66 per share. For each unit consisting of either a share of common stock or Series B Preferred Stock and a warrant to purchase 0.35 of a share of common stock, the purchasers in the June 2012 Private Placement paid a negotiated price of $2.355. The warrants are immediately exercisable and will expire on June 26, 2017, five years from the original issuance date of June 27, 2012. The Company received net proceeds, after deducting placement agents' fees and other transaction expenses, of approximately $17,100 from the 2012 Private Placement. Each share of Series B Preferred Stock is convertible into one share of the Company's common stock at any time at the option of the holder, except that the securities purchase agreement that the Company entered into in connection with the 2012 Private Placement (the "Securities Purchase Agreement") provides that a holder will be prohibited from converting shares of Series B Preferred Stock into shares of common stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than 9.98% of the total number of shares of common stock then issued and outstanding. In the event of the Company's liquidation, dissolution or winding up, holders of the Series B Preferred Stock will receive a payment equal to $0.01 per share of Series B Preferred Stock before any proceeds are distributed to the holders of common stock. After the payment of this preferential amount, and subject to the rights of holders of any class or series of capital stock specifically ranking by its terms senior to the Series B Preferred Stock, holders of Series B Preferred Stock and holders of the Company's Series A Preferred Stock will participate ratably in the distribution of any remaining assets with the common stock and any other class or series of capital stock that participates with the common stock in such distributions. Shares of Series B Preferred Stock will generally have no voting rights, except as required by law and except that the consent of the holders of a majority of the outstanding Series B Preferred Stock will be required to amend the terms of the Series B Preferred Stock. Holders of Series B Preferred Stock are entitled to receive, and the Company is required to pay, dividends on shares of the Series B Preferred Stock equal (on an as-if-converted-to-common-stock basis) to and in the same form as dividends (other than dividends in the form of common stock) actually paid on shares of the common stock when, as and if such dividends (other than dividends in the form of common stock) are paid on shares of the common stock.
	As required by the Securities Purchase Agreement, the Company filed a Registration Statement on Form S-3 (the "Registration Statement") with the Securities and Exchange Commission (the "SEC") on July 27, 2012, which was within 30 days after the closing of the 2012 Private Placement. The Registration Statement, which was declared effective on August 13, 2012, registers the resale of the shares of common stock and Series B Preferred Stock issued and sold in the 2012 Private Placement, the shares of common stock issuable upon conversion of the Series B Preferred Stock issued and sold in the 2012 Private Placement, and the shares of common stock issuable upon exercise of the warrants issued and sold in the 2012 Private Placement. Pursuant to the terms of the Securities Purchase Agreement, the Company agreed to pay liquidated damages to the purchasers in the 2012 Private Placement if, after effectiveness of the Registration Statement and subject to certain specified exceptions, the Company suspends the use of the Registration Statement or the Registration Statement ceases to remain continuously effective as to all the securities for which it is required to be effective (each such event, a "Registration Default"). Subject to specified exceptions, for each 30-day period or portion thereof during which a Registration Default remains uncured, the Company is obligated to pay liquidated damages to each purchaser in cash in an amount equal to 1.0% of the aggregate purchase price paid by each such purchaser in the 2012 Private Placement, up to a maximum of 8.0% of such aggregate purchase price. As of the date of these financial statements, the Company does not believe that it is probable that it will be obligated to pay any such liquidated damages. Accordingly, the Company has not established an accrual for liquidated damages.
	In the event that the Company enters into a merger or change of control transaction, the holders of the warrants issued in the 2012 Private Placement will be entitled to receive consideration as if they had exercised the warrants immediately prior to such transaction, or they may require the Company to purchase the unexercised warrants at the Black-Scholes value (as defined in the warrant) of the warrant on the date of such transaction. The holders have up to 30 days following any such transaction to exercise this right. As a result of this provision, the Company recognizes the warrants as liabilities at their fair value on each reporting date.
	At March 31, 2014, the fair value of the warrant liability determined utilizing the Black-Scholes valuation model was approximately $3,599. In comparison, the fair value of the warrant liability at September 30, 2013 was $4,958.
	During the three and six months ended March 31, 2014, the Company recorded an adjustment to fair value of common stock warrant liability of $568 and $(1,359) respectively, within Other (income)/expense, to reflect a decrease in the valuation of the warrants from September 30, 2013 to March 31, 2014.
	The following summarizes the changes in value of the warrant liability from September 30, 2013 through March 31, 2014:
		Balance at September 30, 2013	$	4,958
		Decrease in fair value of common stock warrant liability		(1,359	)
		Balance at March 31, 2014	$	3,599
	May 2011 Registered Direct Offering
	In May 2011, the Company completed a registered direct offering (the "May 2011 Offering") of an aggregate of 3,018,736 shares of the Company's common stock, 1,813,944 shares of the Company's Series A Preferred Stock and warrants to purchase 2,256,929 shares of the Company's common stock. The shares and warrants were sold in units consisting of (i) one share of common stock and (ii) one warrant to purchase 0.1625 of a share of common stock, at an exercise price of $9.92 per share of the Company's common stock. However, one investor also purchased units consisting of one share of Series A Preferred Stock and a warrant to purchase 0.1625 of a share of common stock. No fractional warrants were issued. Each unit was sold at a price of $8.64 per unit. These units were not issued or certificated. The shares and warrants were immediately separated. The warrants will expire on May 17, 2016, five years from the original issuance date of May 18, 2011. The Company received net proceeds, after deducting placement agents' fees and other offering expenses, of approximately $28,000 from the May 2011 Offering. Each share of Series A Preferred Stock is convertible into one quarter of a share of the Company's common stock at any time at the option of the holder, provided that the holder will be prohibited from converting the shares of Series A Preferred Stock into shares of the Company's common stock if, as a result of such conversion, the holder, together with its affiliates, would beneficially own more than 9.98% of the total number of shares of the Company's common stock then issued and outstanding. In the event of the Company's liquidation, dissolution or winding up, holders of the Series A Preferred Stock will receive a payment equal to $0.01 per share of Series A Preferred Stock before any proceeds are distributed to the holders of the Company's common stock. After the payment of this preferential amount, and subject to the rights of holders of any class or series of capital stock specifically ranking by its terms senior to the Series A Preferred Stock, holders of Series A Preferred Stock will participate ratably in the distribution of any remaining assets with the Company's common stock and any other class or series of capital stock that participates with the common stock in such distributions. Shares of Series A Preferred Stock will generally have no voting rights, except as required by law and except that the consent of the holders of a majority of the outstanding Series A Preferred Stock will be required to amend the terms of the Series A Preferred Stock. The Series A Preferred Stock will not be entitled to receive any dividends, unless and until specifically declared by the Company's board of directors.In the event that the Company enters into a merger or change of control transaction, the holders of the warrants issued in the May 2011 Offering will be entitled to receive consideration as if they had exercised the warrants immediately prior to such transaction, or they may require the Company to purchase the unexercised warrants at the Black-Scholes value (as defined in the warrant) of the warrant on the date of such transaction. As per terms of the warrant, the holders have up to 30 days following any such transaction to exercise this right. As a result of this provision, the Company recognizes the warrants as liabilities at their fair value on each reporting date.
	At March 31, 2014, the fair value of the warrant liability determined utilizing the Black-Scholes valuation model was approximately $361. In comparison, the fair value of the warrant liability at September 30, 2013 was $1,163.
	During the three and six months ended March 31, 2014, the Company recorded an adjustment to fair value of common stock warrant liability of $(142) and $(802), respectively, within Other (income)/expense, to reflect a decrease in the valuation of the warrants from September 30, 2013 to March 31, 2014.
	The following summarizes the changes in value of the warrant liability from September 30, 2013 through March 31, 2014:
		Balance at September 30, 2013	$	1,163
		Decrease in fair value of common stock warrant liability		(802	)
		Balance at March 31, 2014	$	361
	Fair Value Assumptions Used in Accounting for Warrant Liability
	The Company has determined its warrant liability to be a Level 3 fair value measurement and used the Black-Scholes valuation model to calculate, as of March 31, 2013, the fair value of the warrants issued in the June 2012 Private Placement and the May 2011 Offering.
	As of March 31, 2014, the Company estimated such fair value using the following assumptions:
		June 2012 Financing		31-Mar-14
		Stock price	$	2.73
		Exercise price	$	2.66
		Risk-free interest rate		0.9	%
		Expected remaining term		3.24
		Expected volatility		77	%
		Dividend yield		—
		Warrants outstanding		2,749,469
		May 2011 Offering		31-Mar-14
		Stock price	$	2.73
		Exercise price	$	9.92
		Risk-free interest rate		0. 44	%
		Expected remaining term		2.13
		Expected volatility		67	%
		Dividend yield		—
		Warrants outstanding		2,256,929
	Risk-Free Interest Rate. This is the United States Treasury rate for the measurement date having a term equal to the expected remaining term of the warrant. An increase in the risk-free interest rate will increase the fair value and the associated derivative liability.
	Term of Warrants. This is the period of time over which the warrant is expected to remain outstanding and is based on management's estimate, taking into consideration the remaining contractual life.
	Expected Volatility. This is a measure of the amount by which the stock price has fluctuated or is expected to fluctuate. The Company uses a weighted-average of its historic volatility over the retrospective period corresponding to the expected remaining term of the warrants on the measurement date. An increase in the expected volatility will increase the fair value and the associated derivative liability.
	Dividend Yield. The Company has not made any dividend payments nor does it have plans to pay dividends in the foreseeable future. An increase in the dividend yield will decrease the fair value and the associated derivative liability.
	Participating Securities
	If at any time the Company grants, issues or sells securities or other property to holders of any class of common stock, the holders of the warrants are entitled to also acquire those same securities as if they held the number of shares of common stock acquirable upon complete exercise of the warrants.
	As such, given that the warrant holders will participate fully on any dividends or dividend equivalents, the Company determined that the warrants are participating securities and therefore are subject to ASC 260-10-55 earnings per share. These securities were excluded from the three and six months ended March 31, 2013and March 31, 2014 loss per share calculation since their inclusion would be anti-dilutive.

Commitments

Commitments	6 Months Ended
	Mar. 31, 2014
Commitments [Abstract]	'
Commitments	'
	10. Commitments
	Leases
	As of March 31, 2014, the Company leased three facilities in Danbury, Connecticut.
	The Company renewed its lease for laboratory space in November 2013 for one year. This lease provides for annual basic lease payments of $68, plus the annual Consumers Price Index ("CPI") increase for October, not to exceed 6%, plus operating expenses.
	The Company also renewed its lease agreement for additional office space adjacent to its laboratory space in November 2013 for one year. This lease provides for annual basic lease payments of $31, plus the annual CPI increase for October, not to exceed 6%, plus operating expenses.
	In November 2013, the Company renewed its lease for its corporate office for five years. This lease provides for annual basic lease payments of $388, plus the annual CPI increase for May, not to exceed 6%, plus operating expenses.
	Rent expense for the three and six months ended March 31, 2014, was $145 and $310, respectively. In comparison, rent expense for the three and six months ended March 31, 2013, was $152 and $317, respectively.
	Other Commitments
	The Company has entered into certain licensing and collaboration agreements for products currently under development. The Company may be obligated in future periods to make additional payments, which would become due and payable only upon the achievement of certain research and development, regulatory, and approval milestones. The specific timing of such milestones cannot be predicted and depend upon future discretionary research and clinical developments, as well as, regulatory agency actions. Further, under the terms of certain agreements the Company may be obligated to pay commercial milestones contingent upon the realization of sales revenues and sublicense revenues. Due to the long range nature of such commercial milestones, they are neither probable at this time nor predictable, and consequently are not considered contingent milestone payment amounts.

Government_Grants

Government Grants	6 Months Ended
	Mar. 31, 2014
Government Grants [Abstract]	'
Government Grants	'
	11. Government Grants
	Grants received are recognized as grant income when the grants become receivable, provided there is reasonable assurance that the Company will comply with the conditions attached to the grant and there is reasonable assurance the grant will be received. The Company requests cash funding under approved grants as expenses are incurred (not in advance) and reports these receipts on the statement of operations as a separate line item entitled "Government Grants." The corresponding expenses are included in research and development expenses. In July and September 2012, the Company was awarded two National Institutes of Health grants for the development of a concentrated ultra-rapid-acting insulin formulation and a stable glucagon formulation, respectively, for use in an artificial pancreas. Both awards are for two years and total approximately $582 and $583, respectively.
	Work on the grant for the development of a concentrated ultra-rapid-acting insulin formulation started in August 2012 and expenses incurred were $57 and $98, respectively for the three and six months ended March 31, 2014 and $8 and $203, respectively, for the three and six months ended March 31, 2013. Total expenses incurred and grant income received, from inception through March 31, 2014, are $513, which leaves a balance of $69 on the grant for the development of a concentrated ultra-rapid-acting insulin formulation.
	Work on the grant for the stable glucagon formulation started in January 2013 and expenses incurred were $150 and $206 respectively, for the three and six months ended March 31, 2014 and $21 for both the three and six months ended March 31, 2013. Total expenses incurred and grant income received, from inception through March 31, 2014, are $425, which leaves a balance of $158 on the grant for a stable glucagon formulation.
	The Company reported grant income of $207 and $304 respectively, for the three and six months ended March 31, 2014.

Fair_Value_of_Financial_Instru1

Fair Value of Financial Instruments (Tables)	6 Months Ended
	Mar. 31, 2014
Fair Value of Financial Instruments [Abstract]	'
Company's financial assets and liabilities carried at fair value and measured on a recurring basis	'
		Description		Fair Value at			Quoted Prices in		Significant Other		Significant
				31-Mar-14			Active Markets for		Observable		Unobservable
							Identical Assets		Market Inputs		Inputs
							(Level 1)		(Level 2)		(Level 3)
		Assets:
		Cash and cash equivalents	$	28,686		$	28,686	$	—	$	—
		Subtotal		28,686			28,686		—		—
		Liabilities:
		Common stock warrant liability (see Note 9)		(3,960	)		—		—		(3,960	)
		Subtotal		(3,960	)		—		—		(3,960	)
		Total	$	24,726		$	28,686	$	—	$	(3,960	)
		Description		Fair Value at			Quoted Prices in		Significant Other		Significant
				30-Sep-13			Active Markets for		Observable		Unobservable
							Identical Assets		Market Inputs		Inputs
							(Level 1)		(Level 2)		(Level 3)
		Assets:
		Cash and cash equivalents	$	39,781		$	39,781	$	—	$	—
		Subtotal		39,781			39,781		—		—
		Liabilities:
		Common stock warrant liability (see Note 9)		(6,121	)		—		—		(6,121	)
		Subtotal		(6,121	)		—		—		(6,121	)
		Total	$	33,660		$	39,781	$	—	$	(6,121	)
Company recognizes transfers into and out of the level 3	'
		Balance at September 30, 2013	$	(6,121	)
		Decrease in fair value of common stock warrant liability		2,161
		Balance at March 31, 2014	$	(3,960	)

StockBased_Compensation_Tables

Stock-Based Compensation (Tables)	6 Months Ended
	Mar. 31, 2014
Stock-Based Compensation [Abstract]	'
Summary of the stock option activity	'
				Number			Weighted			Weighted			Aggregate
							Average			Average			Intrinsic
							Exercise			Remaining			Value
							Price			Contractual
										Life in Years
		Outstanding options, September 30, 2013		1,920,051		$	22.26			4		$	445
		Granted		1,267,000			2.41						—
		Exercised		(19,241	)		2.48
		Forfeited, expired		(282,285	)		5.96						—
		Outstanding options, March 31, 2014		2,885,525		$	15.27			5			531
		Exercisable options, March 31, 2014		1,441,668		$	28.09			3		$	50
Black-Scholes valuation model assumptions	'
				Three Months Ended						Six Months Ended
				March 31,						March 31,
				2013			2014			2013			2014
		Expected life (in years)		2.39 - 3.77			3.77 - 4.75			2.39 - 4.75			3.77 - 4.75
		Expected volatility		80 - 87	%		73 - 83	%		80 - 90	%		70 - 83	%
		Expected dividend yield		0	%		0	%		0	%		0	%
		Risk-free interest rate		0.25 - 0.36	%		0.69 - 0.78	%		0.25 - 0.75	%		0.58 - 0.78	%
		Weighted average grant date fair value	$	2.86		$	3.35		$	2.43		$	2.41
Stock-based compensation expense associated with the RSUs	'
				Three Months Ended						Six Months Ended
				March 31,						March 31,
				2013			2014			2013			2014
		Stock compensation expense — RSUs	$	110		$	0		$	199		$	54
Summary of RSU activity	'
				Shares			Weighted
							Average
							Grant-Date
							Fair Value
		Non-vested and outstanding balance at October 1, 2013		31,296		$	10.48
		Changes during the period:
		RSUs granted		—			—
		RSUs converted to common stock		(21,468	)		10.48
		RSUs withheld for tax payments		(9,828	)		10.48
		Non-vested and outstanding RSU balance at March 31, 2014		—		$	—

Net_Loss_per_Share_Tables

Net Loss per Share (Tables)	6 Months Ended
	Mar. 31, 2014
Net Loss Per Share [Abstract]	'
Dilutive common shares excluded from the calculation of weighted average common shares outstanding	'
			Three Months Ended		Six Months Ended
			March 31,		March 31,
			2013	2014	2013	2014
		Common shares underlying warrants issued for common stock	5,006,398	5,006,398	5,006,398	5,006,398
		Common shares issuable upon conversion of Series A Preferred Stock	453,486	—	453,486	—
		Common shares issuable upon conversion of Series B Preferred Stock	3,605,607	1,950,000	3,605,607	1,950,000
		Stock options	1,983,297	2,885,525	1,983,297	2,885,525
		Restricted stock units outstanding	31,302	—	31,302	—

Financings_Tables

Financings (Tables)	6 Months Ended
	Mar. 31, 2014
Class of Warrant or Right [Line Items]	'
Fair value assumptions used in accounting for warrant liability	'
		June 2012 Financing		31-Mar-14
		Stock price	$	2.73
		Exercise price	$	2.66
		Risk-free interest rate		0.9	%
		Expected remaining term		3.24
		Expected volatility		77	%
		Dividend yield		—
		Warrants outstanding		2,749,469
		May 2011 Offering		31-Mar-14
		Stock price	$	2.73
		Exercise price	$	9.92
		Risk-free interest rate		0. 44	%
		Expected remaining term		2.13
		Expected volatility		67	%
		Dividend yield		—
		Warrants outstanding		2,256,929
May 2011 registered direct offering [Member]	'
Class of Warrant or Right [Line Items]	'
Summary of changes in value of the warrant liability in private placement	'
		Balance at September 30, 2013	$	1,163
		Decrease in fair value of common stock warrant liability		(802	)
		Balance at March 31, 2014	$	361
June 2012 Private Placement [Member]	'
Class of Warrant or Right [Line Items]	'
Summary of changes in value of the warrant liability in private placement	'
		Balance at September 30, 2013	$	4,958
		Decrease in fair value of common stock warrant liability		(1,359	)
		Balance at March 31, 2014	$	3,599

Business_and_Basis_of_Presenta1

Business and Basis of Presentation (Details)	1 Months Ended
	Jun. 30, 2012
Business and Basis of Presentation (Textual)	'
Description of reverse stock split of outstanding common stock	'one-for-four

Fair_Value_of_Financial_Instru2

Fair Value of Financial Instruments (Details) (USD $)	Mar. 31, 2014	Sep. 30, 2013
In Thousands, unless otherwise specified
Assets:	'	'
Cash and cash equivalents	$28,686	$39,781
Liabilities:	'	'
Common stock warrant liability (see Note 9)	3,960	6,121
Recurring [Member]	'	'
Assets:	'	'
Cash and cash equivalents	28,686	39,781
Subtotal	28,686	39,781
Liabilities:	'	'
Common stock warrant liability (see Note 9)	-3,960	-6,121
Subtotal	-3,960	-6,121
Total	24,726	33,660
Recurring [Member] | Quoted Prices in Active Markets for Identical Assets (Level 1) [Member]	'	'
Assets:	'	'
Cash and cash equivalents	28,686	39,781
Subtotal	28,686	39,781
Liabilities:	'	'
Common stock warrant liability (see Note 9)	'	'
Subtotal	'	'
Total	28,686	39,781
Recurring [Member] | Significant Other Observable Market Inputs (Level 2) [Member]	'	'
Assets:	'	'
Cash and cash equivalents	'	'
Subtotal	'	'
Liabilities:	'	'
Common stock warrant liability (see Note 9)	'	'
Subtotal	'	'
Total	'	'
Recurring [Member] | Significant Unobservable Inputs (Level 3) [Member]	'	'
Assets:	'	'
Cash and cash equivalents	'	'
Subtotal	'	'
Liabilities:	'	'
Common stock warrant liability (see Note 9)	-3,960	-6,121
Subtotal	-3,960	-6,121
Total	($3,960)	($6,121)

Fair_Value_of_Financial_Instru3

Fair Value of Financial Instruments (Details 1) (USD $)	6 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014
Reconcilliation of Level 3 changes	'
Beginning Balance	($6,121)
Decrease in fair value of common stock warrant liability	2,161
Ending Balance	($3,960)

StockBased_Compensation_Detail

Stock-Based Compensation (Details) (Stock options [Member], USD $)	6 Months Ended
In Thousands, except Share data, unless otherwise specified	Mar. 31, 2014
Stock options [Member]	'
Summary of the stock option activity	'
Beginning balance, Outstanding options, Number	1,920,051
Granted, Number	1,267,000
Excercised, Number	-19,241
Forfeited, expired, Number	-282,285
Ending balance, Outstanding options, Number	2,885,525
Exercisable options, Number	1,441,668
Beginning balance, Outstanding options, Weighted Average Exercise Price	$22.26
Granted, Weighted Average Exercise Price	$2.41
Exercised, Weighted Average Exercise Price	$2.48
Forfeited, expired, Weighted Average Exercise Price	$5.96
Ending balance, Outstanding options, Weighted Average Exercise Price	$15.27
Exercisable options, Weighted Average Exercise Price	$28.09
Beginning balance, Outstanding options, Weighted Average Remaining Contractual Life in Years	'4 years
Ending balance, Outstanding options, Weighted Average Remaining Contractual Life in Years	'5 years
Exercisable options, Weighted Average Remaining Contractual Life in Years	'3 years
Beginning balance, Outstanding options, Aggregate Intrinsic Value	$445
Granted, Aggregate Intrinsic Value	'
Exercised, Aggregate Intrinsic Value	'
Forfeited, expired, Aggregate Intrinsic Value	'
Ending balance, Outstanding options, Aggregate Intrinsic Value	531
Exercisable options, Aggregate Intrinsic Value	$50

StockBased_Compensation_Detail1

Stock-Based Compensation (Details 1) (USD $)	3 Months Ended		6 Months Ended
	Mar. 31, 2014	Mar. 31, 2013	Mar. 31, 2014	Mar. 31, 2013
Black-Scholes pricing model assumptions	'	'	'	'
Expected dividend yield	0.00%	0.00%	0.00%	0.00%
Weighted average grant date fair value	$3.35	$2.86	$2.41	$2.43
Minimum [Member]	'	'	'	'
Black-Scholes pricing model assumptions	'	'	'	'
Expected life (in years)	'3 years 9 months 7 days	'2 years 4 months 21 days	'3 years 9 months 7 days	'2 years 4 months 21 days
Expected volatility	73.00%	80.00%	70.00%	80.00%
Risk-free interest rate	0.69%	0.25%	0.58%	0.25%
Maximum [Member]	'	'	'	'
Black-Scholes pricing model assumptions	'	'	'	'
Expected life (in years)	'4 years 9 months	'3 years 9 months 7 days	'4 years 9 months	'4 years 9 months
Expected volatility	83.00%	87.00%	83.00%	90.00%
Risk-free interest rate	0.78%	0.36%	0.78%	0.75%

StockBased_Compensation_Detail2

Stock-Based Compensation (Details 2) (Restricted Stock Units [Member], USD $)	3 Months Ended		6 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013	Mar. 31, 2014	Mar. 31, 2013
Restricted Stock Units [Member]	'	'	'	'
Stock-based compensation expense associated with the RSUs	'	'	'	'
Stock compensation expense - RSUs	$0	$110	$54	$199

StockBased_Compensation_Detail3

Stock-Based Compensation (Details 3) (USD $)	Mar. 31, 2014	Sep. 30, 2013	Mar. 31, 2014
			Restricted stock units (RSUs) [Member]
Summary of RSUs activities	'	'	'
Non-vested and outstanding balance	'	31,296	31,296
Non-vested and outstanding balance, Weighted Average Grant-Date Fair Value	'	$10.48	$10.48
Changes during the period:	'	'	'
RSUs granted, Shares	'	'	'
RSUs granted, Weighted Average Grant-Date Fair Value	'	'	'
RSUs converted to common stock, Shares	'	'	-21,468
RSUs converted to common stock, Weighted average grant date fair value	'	'	$10.48
RSUs withheld for tax payments, Share	'	'	-9,828
RSUs withheld for tax payments, Weighted average grant date fair value	'	'	$10.48
Non-vested and outstanding balance	'	31,296	'
Non-vested and outstanding balance, Weighted average grant date fair value	'	$10.48	'

StockBased_Compensation_Detail4

Stock-Based Compensation (Details Textual) (USD $)	3 Months Ended		6 Months Ended
In Thousands, except Share data, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013	Mar. 31, 2014	Mar. 31, 2013
Stock-Based Compensation (Textual)	'	'	'	'
Compensation cost related to employees and directors	$214	$346	$509	$890
Total compensation cost related to non-vested options not yet recognized	1,444	'	1,444	'
2010 Stock Incentive Plan [Member]	'	'	'	'
Stock-Based Compensation (Textual)	'	'	'	'
Vesting period	'	'	'4 years	'
Contractual life of option granted	'	'	'7 years	'
2010 Restricted Stock Units [Member]	'	'	'	'
Stock-Based Compensation (Textual)	'	'	'	'
Annual Forfeiture Rate For Employee	'	'	7.50%	'
2005 Employee Stock Purchase Plan [Member]	'	'	'	'
Stock-Based Compensation (Textual)	'	'	'	'
Contribution by eligible employees under purchase plan	'	'	15.00%	'
Description of purchase price	'	'	'Lower of: 85% of the fair market value per share on the start date of the offering period in which the employee is enrolled or 85% of the fair market value per share on the semi-annual purchase date.	'
Limitation upon a participant's right to acquire common stock	'	'	'5% or more	'
Maximum period within which election must be made	'	'	'30 days	'
Length of offering period	'	'	'27 months	'
Compensation charge/(credit) in connection with purchase plan	$2	$3	$1	($7)
Common stock reserved for issuance pursuant to purchase rights to be granted	500,000	'	500,000	'
Provision for share replenishment	'	'	'Lesser of 1% of the total number of shares of common stock outstanding on that date or 25,000 shares.	'
Shares reserved and available for issuance under purchase plan	'	'	386,880	377,646
Total shares issued under purchase plan	'	'	113,120	97,354

Reverse_Stock_Splits_Details

Reverse Stock Splits (Details) (USD $)	1 Months Ended
	Jun. 30, 2012	Jun. 11, 2012
Reverse Stock Split (Textual)	'	'
Number of authorized shares after post split	'	25,000,000
Authorized common shares prior to reverse stock split	'	100,000,000
Fractional shares issued from in connection with the reverse stock split	0	'
Cash paid during reverse stock splits in lieu of fractional shares	$0.30	'

Stockholders_Equity_Details

Stockholders' Equity (Details) (USD $)	1 Months Ended				1 Months Ended	12 Months Ended
	31-May-07	Mar. 31, 2014	Dec. 20, 2013	Sep. 30, 2013	Aug. 31, 2013	Sep. 30, 2013
					Series A Preferred Stock [Member]	Series B Preferred Stock [Member]
Stockholders' Equity (Textual)	'	'	'	'	'	'
Common stock, par value	'	$0.01	'	$0.01	'	'
Common stock, shares authorized	'	62,500,000	'	62,500,000	'	'
Common stock authorized before amendment	'	'	25,000,000	'	'	'
Preferred stock available for conversion	'	'	'	'	1,813,944	1,655,607
Shares of common stock issued upon conversion of preferred stock	1,601,749	'	'	'	453,483	1,655,607
Convertible description	'	'	'	'	'convertible at a 4:1 ratio	'

Income_Taxes_Details

Income Taxes (Details) (USD $)	3 Months Ended	6 Months Ended
In Millions, unless otherwise specified	Mar. 31, 2013	Mar. 31, 2014
Income Taxes (Textual)	'	'
Limitations of federal research and development credit carryovers	'	'50% or more change in ownership in the Company within a three-year period.
Total federal losses (prior to the Section 382 limitation)	'	$58
Expiration of net operating loss carryforwards	'	'Expire beginning in 2024 through 2033.
Effective tax rate due to the effects of state income taxes and valuation allowance	0.00%	0.00%
Federal statutory rate	'	34.00%

Net_Loss_per_Share_Details

Net Loss per Share (Details)	3 Months Ended		6 Months Ended
	Mar. 31, 2014	Mar. 31, 2013	Mar. 31, 2014	Mar. 31, 2013
Common shares underlying warrants issued for common stock [Member]	'	'	'	'
Dilutive common shares excluded from the calculation of weighted average common shares outstanding	'	'	'	'
Amount of options, warrants, preferred stock and RSUs	5,006,398	5,006,398	5,006,398	5,006,398
Common shares issuable upon conversion of Series A Preferred Stock [Member]	'	'	'	'
Dilutive common shares excluded from the calculation of weighted average common shares outstanding	'	'	'	'
Amount of options, warrants, preferred stock and RSUs	'	453,486	'	453,486
Common shares issuable upon conversion of Series B Preferred Stock [Member]	'	'	'	'
Dilutive common shares excluded from the calculation of weighted average common shares outstanding	'	'	'	'
Amount of options, warrants, preferred stock and RSUs	1,950,000	3,605,607	1,950,000	3,605,607
Stock options [Member]	'	'	'	'
Dilutive common shares excluded from the calculation of weighted average common shares outstanding	'	'	'	'
Amount of options, warrants, preferred stock and RSUs	2,885,525	1,983,297	2,885,525	1,983,297
Restricted stock units outstanding [Member]	'	'	'	'
Dilutive common shares excluded from the calculation of weighted average common shares outstanding	'	'	'	'
Amount of options, warrants, preferred stock and RSUs	'	31,302	'	31,302

Financings_Details

Financings (Details) (USD $)	6 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014
May 2011 registered direct offering [Member]	'
Summary of changes in fair value of warrant liability	'
Beginning Balance	$1,163
Decrease in fair value of common stock warrant liability	-802
Ending Balance	361
June 2012 Private Placement [Member]	'
Summary of changes in fair value of warrant liability	'
Beginning Balance	4,958
Decrease in fair value of common stock warrant liability	-1,359
Ending Balance	$3,599

Financings_Details_1

Financings (Details 1) (USD $)	6 Months Ended
	Mar. 31, 2014
June 2012 Financing [Member]	'
Fair value assumptions used in accounting for warrant liability	'
Stock price	$2.73
Exercise price	$2.66
Risk-free interest rate	0.90%
Expected remaining term	'3 years 2 months 27 days
Expected volatility	77.00%
Dividend yield	'
Warrants outstanding	2,749,469
May 2011 Offering [Member]	'
Fair value assumptions used in accounting for warrant liability	'
Stock price	$2.73
Exercise price	$9.92
Risk-free interest rate	0.44%
Expected remaining term	'2 years 1 month 17 days
Expected volatility	67.00%
Dividend yield	'
Warrants outstanding	2,256,929

Financings_Details_Textual

Financings (Details Textual) (USD $)

6 Months Ended

12 Months Ended

124 Months Ended

1 Months Ended

3 Months Ended

6 Months Ended

1 Months Ended

3 Months Ended

6 Months Ended

1 Months Ended

In Thousands, except Share data, unless otherwise specified

Mar. 31, 2014

Mar. 31, 2013

Sep. 30, 2011

Sep. 30, 2008

Sep. 30, 2007

Mar. 31, 2014

Jul. 22, 2013

Jun. 24, 2013

Jun. 30, 2012

Mar. 31, 2014

Mar. 31, 2014

Dec. 31, 2013

Sep. 30, 2013

Jun. 30, 2012

Jun. 30, 2012

Jun. 30, 2012

31-May-11

Mar. 31, 2014

Mar. 31, 2014

Dec. 31, 2013

Sep. 30, 2013

31-May-11

31-May-11

31-May-11

31-May-11

June 2013 Public Offering [Member]

June 2013 Public Offering [Member]

June 2012 Private Placement [Member]

June 2012 Private Placement [Member]

June 2012 Private Placement [Member]

June 2012 Private Placement [Member]

June 2012 Private Placement [Member]

June 2012 Private Placement [Member]

June 2012 Private Placement [Member]

June 2012 Private Placement [Member]

May 2011 Offering [Member]

May 2011 Offering [Member]

May 2011 Offering [Member]

May 2011 Offering [Member]

May 2011 Offering [Member]

May 2011 Offering [Member]

May 2011 Offering [Member]

May 2011 Offering [Member]

Registered Direct Offering [Member]

Common Stock [Member]

Common Stock [Member]

Common Stock [Member]

Series B Preferred Stock [Member]

Warrant [Member]

Common Stock [Member]

Series A Preferred Stock [Member]

Warrant [Member]

Financing (Textual)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Issuance of shares under private placement

'

'

'

'

'

'

'

4,482,760

'

'

'

'

'

4,250,020

3,605,607

2,749,469

'

'

'

'

'

'

'

'

'

Issuance of shares under direct registered offering

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

3,018,736

1,813,944

2,256,929

'

Warrant exercise price

'

'

'

'

'

'

'

'

$2.66

'

'

'

'

'

'

'

$9.92

'

'

'

'

'

'

'

$9.92

Common shares issued for each warrant

'

'

'

'

'

'

'

'

'0.35 of a share of common stock

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'0.1625 of a share of common stock

Price of unit

'

'

'

'

'

'

$4.35

$4.35

$2.36

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$8.64

Warrants issuance date

'

'

'

'

'

'

'

'

27-Jun-12

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

18-May-11

Expiration date of warrant

'

'

'

'

'

'

'

'

26-Jun-17

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

17-May-16

Warrants expiration period

'

'

'

'

'

'

'

'

'5 years

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'5 years

Proceed from issuance of private placement, net

'

'

'

'

'

$8,587

'

$19,300

$17,100

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$28,000

Common shares issued after conversion of preferred stock

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1

'

'

'

'

'

'

'

'

'

'

Mimimum benefit owned by holder on conversion of preferred stock

'

'

'

'

'

'

'

'

'

'

'

'

'

'

9.98%

'

9.98%

'

'

'

'

'

9.98%

'

'

Per share payment to preferred stock holder before common stock

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$0.01

'

'

'

'

'

'

'

$0.01

'

'

Voting rights of preferred stock

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'no voting rights

'

'

'

'

'

'

'

'

'

'

Period of filing of registration statement

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'within 30 days after the closing of the 2012 Private Placement.

'

'

'

'

'

'

'

'

'

'

Declaration date of registration statement

'

'

'

'

'

'

'

'

'

'

'

'

'

'

13-Aug-12

'

'

'

'

'

'

'

'

'

'

Minimum percentage of purchase price company obligated to pay as liquidated damages

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1.00%

'

'

'

'

'

'

'

'

'

'

Maximum percentage of purchase price company obligated to pay as liquidated damages

'

'

'

'

'

'

'

'

'

'

'

'

'

'

8.00%

'

'

'

'

'

'

'

'

'

'

Fair value of warrant liability

'

'

'

'

'

'

'

'

'

3,031

3,031

5,633

4,958

'

'

'

'

504

504

1,705

1,163

'

'

'

'

Follow up period of holders to pay consideration

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'30 days

'

'30 days

'

'

'

'

'

'

'

'

Warrants exercised

'

'

50

112

423

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Exercise of warrants

'

'

'

'

'

585

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Issuance of common stock and warrants to purchase additional shares of common stock

'

'

'

'

'

'

236,007

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Income from adjustment to fair value of common stock warrant liability

'

'

'

'

'

'

'

'

'

$568

$1,359

'

'

'

'

'

'

($142)

($802)

'

'

'

'

'

'

Commitments_Details_Textual

Commitments (Details Textual) (USD $)	3 Months Ended		6 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013	Mar. 31, 2014	Mar. 31, 2013
	Facility		Facility
Commitments (Textual)	'	'	'	'
Number of facilities leased	3	'	3	'
Rent expense	$145	$152	$310	$317
Laboratory Space [Member]	'	'	'	'
Commitments (Textual)	'	'	'	'
Additionally period for renewal of lease	'	'	'1 year	'
Leases amendment description	'	'	'Lease provides for annual basic lease payments of $68, plus the annual Consumers Price Index ("CPI") increase for October, not to exceed 6%, plus operating expenses.	'
Annual basic lease payments plus operating expenses	'	'	68	'
Percentage of increase in annual Consumers Price Index (CPI)	'	'	6.00%	'
Office Space [Member]	'	'	'	'
Commitments (Textual)	'	'	'	'
Additionally period for renewal of lease	'	'	'1 year	'
Leases amendment description	'	'	'Lease provides for annual basic lease payments of $31, plus the annual CPI increase for October, not to exceed 6%, plus operating expenses.	'
Annual basic lease payments plus operating expenses	'	'	31	'
Percentage of increase in annual Consumers Price Index (CPI)	'	'	6.00%	'
Corporate Office [Member]	'	'	'	'
Commitments (Textual)	'	'	'	'
Additionally period for renewal of lease	'	'	'5 years	'
Leases amendment description	'	'	'Lease provides for annual basic lease payments of $388, plus the annual CPI increase for May, not to exceed 6%, plus operating expenses.	'
Annual basic lease payments plus operating expenses	'	'	$388	'
Percentage of increase in annual Consumers Price Index (CPI)	'	'	6.00%	'

Government_Grants_Details

Government Grants (Details) (USD $)	3 Months Ended		6 Months Ended		124 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013	Mar. 31, 2014	Mar. 31, 2013	Mar. 31, 2014
Government Grants (Textual)	'	'	'	'	'
Description of grants awards	'	'	'In July and September 2012, the Company was awarded two National Institutes of Health grants.	'	'
Period for grants awards	'	'	'2 years	'	'
Grant one received from government	'	'	$582	'	'
Grant two received from government	'	'	583	'	'
Insulin formulation grant expenses incurred	57	8	98	203	513
Glucagon formulation grant expenses incurred	150	21	206	21	425
Balance of grant income received ultra rapid acting insulin formulation	'	'	69	'	'
Balance of grant income received glucagon formulation	'	'	158	'	'
Grant income received of ultra rapid acting insulin formulation	'	'	'	'	513
Grant income received of glucagon formulation	'	'	'	'	425
Grant income	$207	$29	$304	$224	$938